# eVusheld Assessment reaL wORld Effectiveness at UPMC

> **NCT05667116** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 4232 (actual)

## Conditions studied

- SARS-CoV-2, COVID-19

## Interventions

- **DRUG:** EVUSHELD

## Key facts

- **NCT ID:** NCT05667116
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-09
- **Primary completion:** 2023-07-24
- **Final completion:** 2023-07-24
- **Target enrollment:** 4232 (ACTUAL)
- **Last updated:** 2024-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05667116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05667116, "eVusheld Assessment reaL wORld Effectiveness at UPMC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05667116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*